Phillips, Stephen S.
Mueller, Claire M.
Nogueira, Raul G.
Khalifa, Yousuf M.
Article History
First Online: 27 November 2018
Compliance with Ethical Standards
:
: Raul G. Nogueira declares that he has no conflict of interest related to the topic or work under consideration. Other unrelated disclosures include Stryker Neurovascular (DAWN Trial Principal Investigator—no compensation, TREVO Registry Steering Committee—no compensation, Trevo-2 Trial Principal Investigator—modest; Consultant—modest); Medtronic (SWIFT Trial Steering Committee—modest; SWIFT-Prime Trial Steering Committee—no compensation; STAR Trial Angiographic Core Lab—significant); Penumbra (3D Separator Trial Executive Committee—no compensation); Cerenovus/Neuravi (ENDOLOW Trial Principal Investigator, ARISE-2 trial Steering Committee—no compensation, Physician Advisory Board, modest); Phenox (Physician Advisory Board, modest); Anaconda (Physician Advisory Board, modest); Genentech (Physician Advisory Board—modest); Biogen (Physician Advisory Board—modest); Prolong Pharmaceuticals (Physician Advisory Board—modest); and Allm Inc. (Physician Advisory Board—no compensation). Editor-In-Chief Interventional Neurology Journal (no compensation) and remaining authors declare that they have no conflict of interest.
: This article does not contain any studies with human participants or animals performed by any of the authors.